Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03764735 · ClinicalTrials.gov registry record · Phase 3
Study of SkQ1 as Treatment for Dry-eye Syndrome
A Phase 3 study of Dry Eye Syndrome, sponsored by Mitotech.
- Completed
- Registry status
- Phase 3
- Development phase
- 452
- Enrollment target
- 7
- Study locations
NCT03764735: Completed Phase 3 study of Dry Eye Syndrome, sponsored by Mitotech.
NCT03764735 is a Phase 3 study of Dry Eye Syndrome that has completed, run by Mitotech. The registered enrollment target is 452 participants, above the 120-participant average among 10 other Dry Eye Syndrome trials with a reported enrollment target (277% higher). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03764735, a Phase 3 study of Dry Eye Syndrome, has completed, sponsored by Mitotech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 452 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
Primary Outcome
Change of Corneal Fluorescein Staining from baseline to Day 57, scale ranges from 0 to 4, where grade 0 = None, 4 = Severe
Conditions Studied
Interventions
- DRUG Low Dose - SkQ1
- DRUG High dose - SkQ1
- DRUG SkQ1 (Vehicle)
Study Locations (7)
Arizona
- Cornea & Cataract Consultants of Arizona - Phoenix
California
- Eye Research Foundation - Newport Beach
Kentucky
- Eye Care Insititute - Louisville
Maine
- Central Maine Eye Care - Lewiston
Massachusetts
- Andover Eye Associates - Andover
North Carolina
- Vita Eye Clinic - Shelby
Tennessee
- Total Eye Care, PA - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 452 participants |
| Start Date | 2018-12-06 |
| Est. Completion | 2019-02-09 |
| Phase | Phase 3 |
What the finished NCT03764735 record still lists
NCT03764735 is an interventional study that assigns participants to a tested intervention. The registered 452 participants enrollment target is mid-sized for trials with a published cap, above the 120-participant average among 10 other Dry Eye Syndrome trials with a reported enrollment target (277% higher).
The record links to 1 condition, with Dry Eye Syndrome appearing as the primary indexed condition, and to 3 interventions - of which Low Dose - SkQ1 is the first listed.
NCT03764735 lists 7 locations in 7 states (Arizona, California, Kentucky).
Frequently Asked Questions
What is clinical trial NCT03764735 about?
NCT03764735 is a clinical study titled "Study of SkQ1 as Treatment for Dry-eye Syndrome". The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
What is the current status of trial NCT03764735?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 452 participants. The study started on 2018-12-06. Estimated completion is 2019-02-09.
What conditions does trial NCT03764735 study?
This clinical trial studies the following conditions: Dry Eye Syndrome.
What interventions are being tested in trial NCT03764735?
The interventions under investigation include: Low Dose - SkQ1 (DRUG), High dose - SkQ1 (DRUG), SkQ1 (Vehicle) (DRUG).
Who is sponsoring clinical trial NCT03764735?
This trial is sponsored by Mitotech, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03764735 being conducted?
This trial has 7 study locations across Arizona, California, Kentucky, Maine, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03764735's enrollment target sits among peer trials
452 2nd of 10 the highest of 10 other Dry Eye Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome
COMPLETED · Phase 3
-
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
RECRUITING · Phase 1
-
Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome
COMPLETED · NA
-
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye
COMPLETED · Phase 2
-
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
COMPLETED · Phase 1
-
Effects of Dry Eye Treatments on the Ocular Surface
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05676255 · 452 participants · Phase 2
The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project
- NCT05703178 · 452 participants · Phase 3
Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
- NCT03460977 · 453 participants · Phase 1
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- NCT04708171 · 453 participants
The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI